Adherence with atovaquone-proguanil malaria prophylaxis is high among travelers from a non-endemic region. Adverse effects are minimal. Non-adherence was primarily attributable to travelers' perception of need.

This report presents two cases of Fusobacterium bacteraemia associated with portal vein thrombosis. A 63-year-old man with a history of hypercholesterolaemia and nephrolithiasis was admitted to the hospital with fever and abdominal pain. A computed tomography (CT) scan revealed thrombosis of the posterior right portal vein. Blood cultures were positive for Fusobacterium nucleatum. The second case was a 53-year-old man with alcoholic steatohepatitis admitted with fever, chills and abdominal pain. A CT scan revealed right portal vein thrombosis and Fusobacterium necrophorum was isolated from his blood cultures. Both patients were successfully treated with intravenous ertapenem 1 g day -1 for 4 weeks with resolution of symptoms. These case reports underscore the importance of considering the diagnosis of portal vein thrombosis in patients with Fusobacterium bacteraemia of unclear aetiology.

Lactobacilli are gram-positive bacteria usually found in the normal flora and are commonly used as probiotic treatments for vaginal candidiasis. Lactobacilli are normally considered non-pathogenic; however, certain risk factors can make a patient susceptible to severe infections. This case describes an immunocompetent 61-year-old female with an automated intracardiac defibrillator who presented with a 10-day history of nausea and vomiting. Furthermore, diagnostic tests, including a transesophageal echocardiography, revealed a large vegetation, and blood cultures were consistently positive for Lactobacillus. The patient was treated with intravenous penicillin and gentamicin, along with removal of the automated intracardiac defibrillator. In patients with significant underlying conditions, physicians should consider Lactobacillus as a causative organism to avoid delays in treatment.

Background Coronavirus disease 2019 (COVID-19) is a global pandemic. The disease, typically characterized by bilateral pulmonary infiltrates and profound elevation of inflammatory markers, can range in severity from mild or asymptomatic illness to a lethal cytokine storm and respiratory failure. A number of recognized complications of COVID-19 infection are described in the literature. Common neurological complications include headache and anosmia. Guillain-Barré syndrome (GBS) is an uncommon complication described in isolated case reports. However, a causal relationship has yet to be established. This case report adds to the growing body of evidence that GBS is a potential COVID-19 complication. Case presentation A 70-year-old Caucasian woman with recently diagnosed COVID-19 infection presented to the emergency department with 4 days of gradually worsening ascending lower extremity weakness. Exam revealed bilateral lower extremity weakness, mute reflexes, and sensory loss. Soon after starting intravenous administration of immunoglobulin (IVIG), the patient developed respiratory distress, eventually requiring intubation. She remained intubated for the duration of her IVIG treatment. After five rounds of treatment, the patient was successfully extubated and transferred to acute rehab. Following 4 weeks of intense physical therapy, she was able to walk with assistance on room air. Conclusion At the present time, this is one of the few reports of acute inflammatory demyelinating polyneuropathy (AIDP) or GBS associated with COVID-19 in the United States. It is unclear whether a causal relationship exists given the nature of the syndrome. However, in light of the growing number of reported cases, physicians should be aware of this possible complication when evaluating COVID-19 patients.

A 63-year-old man developed peripheral eosinophilia without evidence of pulmonary involvement while being treated with daptomycin.